Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances

doi:10.3748/wjg.v22.i5.1745

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (24205)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

2828

WORD

299

HTML

16716

Tables (1-1)

234

Sum=20077

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

470

Download

869

Sum=1339

Publishing Process of This Article

Item

Count

Browse

1117

Download

1672

Sum=2789

Feb 7, 2016 (publication date) through Nov 18, 2024

Times Cited of This Article

Times Cited (287)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Feb 7, 2016; 22(5): 1745-1755
Published online Feb 7, 2016. doi: 10.3748/wjg.v22.i5.1745

Table 1 Recommendations for use of tumour markers and biomarkers in colorectal cancer by groups of experts

Biomarker	Applications	ASCO[23,98,99]	ESMO[2,33]	NCCN[100,101]
CEA	Screening	No	None published	None published
	Prognostic factor	Yes	Yes	Yes
	Follow up	Yes	Yes	Yes
CA 19-9	All	No	No	None published
CA 72-4	All	None published	None published	None published
CA 242	All	None published	None published	None published
CA 195	All	None published	None published	None published
CYFRA 21-1	All	None published	None published	None published
MSI	Prognostic factor	No	Yes	Yes
18qLOH	Prognostic factor	Yes	Yes (potentially)	None published
p53 gene	Prognostic factor	No	Yes (potentially)	None published
KRAS	Prognostic factor	None published	Yes (potentially)	None published
KRAS	Predictive factor	Yes	Yes	Yes
BRAF	Prognostic factor	None published	Yes	Yes
BRAF	Predictive factor	Yes	Yes (potentially)	Yes (potentially)
PIK3CA	Predictive factor	None published	Yes (potentially)	None published
PTEN	Predictive factor	Yes (potentially)	Yes (potentially)	None published
UGT1A1	Predictive factor	Yes	Yes (only in case of severe toxicity of irinotecan)	No
VEGF	All	None published	None published	None published
TPA, TPS	All	None published	None published	None published
Ezrin	All	None published	None published	None published
DNA ploidy	All	No	None published	None published
TS	Prognostic factor	No	Yes (potentially)	None published
TS	Prognostic factor	Yes (potentially)	Yes (potentially)	None published
TP	All	No	None published	None published
DPD	Prognostic factor	No	Yes (only in case of severe toxicity of 5-FU)	None published

CEA: Carcinoembryonic antigen; MSI: Microsatellite instability; 18qLOH: Chromosome 18q loss of heterozygosity; VEGF: Vascular endothelial growth factor; TPS: Tissue polypeptide-specific antigen; TPA: Tissue polypeptide antigen.

Citation: Lech G, Słotwiński R, Słodkowski M, Krasnodębski IW. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol 2016; 22(5): 1745-1755
URL: https://www.wjgnet.com/1007-9327/full/v22/i5/1745.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i5.1745